Ovarian Cancer News & Features
The protein cytokeratin 5 (CK5), known to be a marker of poor prognosis in patients with breast cancer, also marks ovarian cancers likely to be resistant to the common chemotherapy cisplatin.
The more children a woman has or whether she has undergone tubal ligation lowers her risk of different types of ovarian cancer to different levels, according to new research presented at the 2015 NCRI Cancer Conference.
A healthy diet may reduce the risk for developing ovarian cancer in African American women.
Patients who develop ovarian cancer may have improved outcomes if they have prior oral contraceptive use.
Venlafaxine has a significant clinical activity against taxane-oxaliplatin-induced acute neurosensory toxicity in patients with cancer.
Ovarian Cancer Clinical Trials
- Chemo, Tamoxifen May Increase VTE Risk Among Patients With Breast Cancer
- Many Patients With HR+ Disease Receive Initial Palliative Chemotherapy, Despite Worse Outcomes
- Risk of Some Cancers Modestly Increased in Persons Who Had Herpes Zoster
- Different Types of Ovarian Cancer Have Different Causes
- Targeted Treatment Produces Rapid Shrinkage of Recurrent BRAF-mutant Brain Tumor
- Breastfeeding Associated With A Reduced Risk of Aggressive Breast Cancer
- Hospitals Should Enact Bereavement Programs, Researchers Urge
- Physical Activity Communications Should be Part of Oncology Care Clinic Visits With Patients
- Communication Practices of Many US Physicians May Be Discouraging HPV Vaccination
- Navigation Program Tackles Cancer Care on Two Fronts
- Suicides Significantly Higher Among Patients With Head and Neck Cancers
- No Racial Disparities in ODX Testing for Node-Negative Breast Cancer
- Weight Loss Counseling Effective in Breast Cancer Survivors
- Carpal Tunnel Syndrome Associated With Anastrozole for Prevention of Breast Cancer
- Existing Drug May Limit Recurrence and Metastasis of Glioblastoma Multiforme
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|